List of Excipients in Branded Drug BLENREP

BLENREP Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

BLENREP (belantamab mafodotin-blmf) uses a conventional lyophilized antibody-drug conjugate formulation built around citrate buffering, trehalose stabilization, and polysorbate 80 protection. The largest excipient opportunities are not commodity supply alone. They are in high-purity biologics-grade materials, low-particulate packaging, container-closure compatibility, ready-to-use presentations, cold-chain resilience, and formulation platforms that can be reused across antibody-drug conjugates (ADCs).

BLENREP’s commercial outlook depends on regulatory re-entry and expansion in multiple myeloma. Its excipient requirements remain relevant because the product’s antibody component, linker-payload chemistry, lyophilized presentation, and intravenous administration create demanding stability and manufacturing requirements.

What excipients are used in BLENREP?

The marketed BLENREP presentation is a sterile, preservative-free, lyophilized powder for intravenous infusion. The 100 mg vial contains belantamab mafodotin-blmf with citric acid, sodium citrate, trehalose dihydrate, and polysorbate 80 as inactive ingredients.[1]

Component	Function in the BLENREP formulation	Commercial relevance
Citric acid	Part of the buffer system; supports pH control	High-volume, low-cost material but requires biologics-grade purity
Sodium citrate	Completes the citrate buffer system	Requires control of ionic strength, endotoxin, metals, and lot consistency
Trehalose dihydrate	Stabilizing sugar for the antibody-drug conjugate during freezing and drying	Higher-value excipient opportunity because grade, moisture, and thermal behavior affect product quality
Polysorbate 80	Surfactant that reduces interfacial and surface-induced aggregation	Critical quality material with oxidation, hydrolysis, peroxide, and particle-control requirements
Water for injection	Used to reconstitute the vial before dilution	Generally supplied by the healthcare facility rather than included in the vial

The label instructs healthcare professionals to reconstitute the vial with sterile water for injection and dilute the resulting solution in 0.9% sodium chloride before intravenous administration.[1] The product does not use a preserved multidose format.

How does the BLENREP formulation work?

BLENREP is an ADC comprising a humanized B-cell maturation antigen antibody linked to a cytotoxic auristatin payload. The formulation must preserve both antibody integrity and the chemical stability of the linker-payload system.

Why trehalose is commercially important

Trehalose is commonly used in biologics because it can reduce structural damage during freezing and lyophilization. In BLENREP, the excipient must support:

• Maintenance of antibody conformation during drying and storage.
• Protection against aggregation during reconstitution.
• Acceptable cake structure and reconstitution time.
• Control of residual moisture.
• Compatibility with the linker-payload and antibody-drug conjugate distribution.

The commercial opportunity is strongest for trehalose dihydrate manufactured under pharmaceutical quality systems, with tight control of bioburden, endotoxin, trace metals, moisture, and particle burden.

A supplier competing for ADC applications must provide more than compendial compliance. Sponsors typically evaluate supplier change history, supply continuity, extractables and leachables data, elemental impurity controls, and documentation suitable for regulatory filings.

Why polysorbate 80 is a high-risk excipient

Polysorbate 80 protects proteins and ADCs from agitation and contact with interfaces during manufacturing, shipping, and preparation. It also has known quality challenges:

• Oxidation and peroxide formation.
• Hydrolytic degradation.
• Variability in fatty-acid composition.
• Subvisible and visible particle generation.
• Potential interaction with primary packaging and delivery components.

For BLENREP, a supplier capable of offering low-peroxide, tightly characterized polysorbate 80 has a stronger commercial position than a supplier selling only standard-grade material. The most defensible opportunities involve analytical methods, stabilized grades, and lot-to-lot consistency.

Potential supplier differentiation includes peroxide limits, fatty-acid profiling, oxidation markers, particle data, and demonstrated compatibility with ADCs rather than conventional monoclonal antibodies.

What formulation and manufacturing opportunities exist around BLENREP?

The highest-value opportunities are in formulation improvement, process control, and presentation redesign.

Lyophilized formulation optimization

The current vial presentation creates operational burdens:

1. Reconstitution requires trained personnel.
2. The product must be diluted before infusion.
3. Preparation introduces handling and transfer steps.
4. Reconstitution time and foaming can affect pharmacy workflow.
5. The product requires refrigerated storage and controlled preparation.

A next-generation formulation could seek improved reconstitution speed, lower foaming, reduced particulate formation, or greater in-use stability. Those changes could support a formulation patent if they produce a measurable technical effect and are claimed with sufficient specificity.

Possible claim categories include:

• Defined trehalose-to-protein ratios.
• Narrow citrate concentration and pH ranges.
• Low-polysorbate formulations.
• Alternative surfactant systems.
• Specified residual-moisture limits.
• Reconstitution-time thresholds.
• Stability after dilution in normal saline.
• Reduced aggregate or particle levels.
• Compatibility with prefilled infusion systems.

A formulation improvement would face a high evidentiary burden. A simple substitution of one standard excipient for another may be vulnerable to obviousness challenges unless supported by unexpected stability, manufacturability, or clinical-use benefits.

Liquid and ready-to-use presentations

A liquid BLENREP presentation could reduce pharmacy preparation steps, but it would create new stability and packaging requirements. The key risks are:

• Long-term aggregation in the liquid state.
• Payload or linker degradation.
• Surfactant oxidation.
• Increased interaction with container surfaces.
• Greater sensitivity to temperature excursions.
• Higher shipping and storage volume.

A ready-to-use product could support a lifecycle-management strategy if it materially reduces preparation time or medication-use errors. The most commercially attractive formats would be a ready-to-dilute vial, a dual-chamber container, or a pharmacy-ready infusion presentation.

Alternative excipient systems

Potential alternatives to the current system include:

• Poloxamers or other nonionic surfactants in place of or alongside polysorbate 80.
• Sucrose or selected sugar-polymer combinations in place of trehalose.
• Histidine or other low-reactivity buffers in place of citrate.
• Amino acids or stabilizing polymers for aggregation control.
• Antioxidant or metal-control strategies to reduce polysorbate and payload degradation.

Each alternative must be assessed against ADC-specific attributes. A formulation that protects the antibody may accelerate linker cleavage, alter drug-antibody ratio measurements, or affect free-payload levels. Formulation screening therefore must measure both biologic and chemical stability.

What FDA regulatory status affects BLENREP commercial opportunities?

BLENREP received accelerated FDA approval in August 2020 for adults with relapsed or refractory multiple myeloma after at least four prior therapies, based on response-rate data.[2] The confirmatory DREAMM-3 trial did not meet its primary progression-free-survival objective against pomalidomide plus low-dose dexamethasone, and the US marketing authorization was subsequently withdrawn.[3]

GSK later pursued a new US regulatory path using data from DREAMM-7, a randomized study evaluating belantamab mafodotin in combination with bortezomib and dexamethasone against daratumumab, bortezomib, and dexamethasone.[4]

Regulatory event	Date or status	Excipient-commercial impact
FDA accelerated approval	August 2020	Established commercial manufacturing and supply base
Confirmatory DREAMM-3 outcome	2023	Increased pressure for indication and formulation efficiency
US withdrawal of original approval	2025	Reduced immediate US demand under the withdrawn indication
DREAMM-7 regulatory submission	2024-2025	Preserved potential for renewed US commercial demand
European and other-market status	Market-specific	Maintains regional demand and supply obligations

The regulatory status directly affects excipient demand forecasts. A US reapproval or expanded indication would increase demand for trehalose, polysorbate 80, citrate components, vials, stoppers, and sterile manufacturing capacity. Without broad re-entry, demand is more dependent on non-US markets and clinical supply.

When does BLENREP lose exclusivity?

BLENREP’s exclusivity position is determined by several layers:

• Active pharmaceutical ingredient and ADC composition patents.
• Antibody or antigen-binding patents.
• Linker-payload and conjugation patents.
• Manufacturing-process patents.
• Formulation patents.
• Method-of-use patents.
• Regulatory exclusivity.
• Orphan-drug or pediatric exclusivity, where applicable.

The US product is a biologic ADC rather than a conventional small-molecule drug. A conventional ANDA generic pathway is not the expected route. A competing product would more likely use a biosimilar or interchangeable-biologic pathway, although ADC-specific comparability issues make the development program more complex than for a standard monoclonal antibody.

The relevant technical barriers include:

• Antibody sequence and binding comparability.
• Drug-to-antibody ratio distribution.
• Conjugation-site distribution.
• Free payload and unconjugated antibody levels.
• Aggregation and particle profiles.
• Glycosylation and charge variants.
• Linker stability.
• Cytotoxic payload release.
• Bioassay comparability.
• Clinical and immunogenicity requirements.

A biosimilar competitor could challenge the biologic’s market position before every formulation or manufacturing patent expires if it establishes a viable regulatory and freedom-to-operate strategy. Excipient patents alone are unlikely to block entry if the competitor uses a non-infringing formulation.

What patent strategy can protect BLENREP excipient innovations?

The most defensible patent strategy would focus on technically narrow, clinically relevant formulation and process claims rather than broad claims to citrate, trehalose, or polysorbate 80 individually.

Potential claim themes include:

Patent theme	Potential commercial value
ADC formulation with defined pH and excipient ranges	Protects a specific stability window
Low-peroxide polysorbate system	Addresses oxidation and particle control
Lyophilization cycle and residual-moisture range	Protects manufacturing know-how
Reconstitution and dilution stability	Supports pharmacy-use differentiation
Ready-to-use liquid presentation	Creates lifecycle and convenience protection
Container-closure compatibility	Supports product-specific packaging claims
Combination treatment method	May protect a new clinical use even when composition rights narrow
Manufacturing process for consistent drug-to-antibody ratio	Can create a difficult process barrier

A patent estate is stronger when formulation claims are supported by comparative data against standard excipient systems. Useful evidence includes reduced aggregation, lower free payload, improved reconstitution, longer in-use stability, or reduced particulate formation.

Which companies could compete in BLENREP-related excipients?

The competitive landscape includes major pharmaceutical excipient suppliers, specialist biologics-grade material producers, contract development and manufacturing organizations, and packaging companies.

Excipient suppliers

Relevant supplier categories include:

• Trehalose and pharmaceutical sugar manufacturers.
• Polysorbate 80 suppliers with biologics-grade offerings.
• Buffer-component manufacturers.
• Custom excipient and formulation-development companies.
• Analytical laboratories specializing in surfactant degradation and particulate characterization.

Companies with established pharmaceutical excipient portfolios include Croda, BASF, Evonik, DuPont legacy excipient businesses, Roquette, Merck, and Thermo Fisher Scientific, although product availability and qualification status vary by region and application.[5]

CDMOs and technology providers

ADC-focused CDMOs can monetize:

• Formulation screening.
• Conjugation-process development.
• Lyophilization cycle development.
• Aseptic fill-finish.
• Stability-indicating analytics.
• Comparability packages for formulation changes.

The strongest commercial proposition is a package that combines excipient selection with ADC-specific analytics. A generic excipient distributor has less negotiating leverage than a provider that can demonstrate lower aggregation, controlled free payload, and validated container compatibility.

What generic and biosimilar launch risks exist?

A BLENREP competitor faces a mixed barrier profile.

Lower barriers

• Citrate, trehalose, and polysorbate 80 are widely available.
• The product is administered intravenously, reducing device complexity.
• A competitor can select a different excipient system.
• Standard biologics manufacturing platforms can support some development activities.

Higher barriers

• ADC comparability is more complex than antibody comparability.
• The cytotoxic payload creates specialized handling requirements.
• Drug-to-antibody ratio and conjugation heterogeneity require advanced analytics.
• Linker-payload stability affects product quality and clinical performance.
• Clinical indication and combination-regimen requirements may limit substitution.
• Regional patent and regulatory positions differ.

The main competitive threat is therefore more likely to arise from a differentiated ADC or a biosimilar-like product with a robust comparability package than from a simple formulation copy.

How does BLENREP compare with other multiple-myeloma biologics?

Product	Modality	Excipient complexity	Competitive implication
BLENREP	ADC	High because antibody, linker, payload, and lyophilization must remain stable	Strong formulation and analytical barriers
Darzalex	Monoclonal antibody	High biologics complexity, but no cytotoxic payload	More established biosimilar development pathway
Empliciti	Monoclonal antibody	Conventional protein formulation requirements	Lower ADC-specific analytical burden
Elrexfio	Bispecific antibody	Complex protein and immunogenicity controls	Competes through a different mechanism and dosing model
Carvykti	CAR-T therapy	Cell-processing rather than conventional excipient strategy	Competes clinically but has a different manufacturing model

BLENREP’s excipient opportunity is narrower than the opportunity around a high-volume monoclonal antibody because demand depends on indication recovery and ADC manufacturing scale. Its technical value per unit can be higher because excipient performance directly affects conjugate quality.

What commercial opportunities are most attractive?

The best opportunities rank as follows:

1. Biologics-grade polysorbate 80 with low oxidation and particle generation.
2. Trehalose supply with tight moisture and endotoxin control.
3. ADC-specific formulation development.
4. Lyophilization and reconstitution optimization.
5. Ready-to-use or reduced-handling presentations.
6. Container-closure systems with low adsorption and extractables.
7. Analytical methods for free payload, aggregates, particles, and surfactant degradation.
8. Regional dual sourcing and supply-chain qualification.

Revenue exposure is tied to three variables: approved indications, treatment duration, and geographic uptake. Excipient suppliers should avoid assuming that historical or projected BLENREP drug sales translate directly into excipient demand. ADC dose intensity, vial size, wastage, manufacturing yield, and formulation concentration can materially change excipient consumption.

Key Takeaways

• BLENREP uses citric acid, sodium citrate, trehalose dihydrate, and polysorbate 80 in a lyophilized intravenous formulation.
• Polysorbate 80 quality is the most technically sensitive excipient issue because oxidation, hydrolysis, and particles can affect ADC quality.
• Trehalose creates opportunities in biologics-grade supply, lyophilization performance, and residual-moisture control.
• A ready-to-use or faster-reconstituting presentation could support lifecycle management and new formulation claims.
• BLENREP’s US commercial demand depends on regulatory recovery following withdrawal of the original accelerated approval.
• Conventional generic substitution is unlikely. Biosimilar-like ADC development faces substantial analytical and manufacturing barriers.
• Excipient patents are strongest when linked to measurable improvements in stability, reconstitution, particles, payload integrity, or manufacturing consistency.
• The most attractive commercial strategy combines excipient supply with ADC-specific formulation, analytical, and fill-finish capabilities.

FAQs

Can polysorbate 80 be replaced in BLENREP?

Yes, a competing formulation could use another surfactant, but the replacement must demonstrate equivalent or improved protection against aggregation, particles, oxidation, and chemical degradation. A substitution could also require regulatory comparability work.

Is BLENREP a biologic for biosimilar purposes?

Yes. Belantamab mafodotin is an antibody-drug conjugate biologic. A follow-on product would need to address antibody comparability and ADC-specific attributes, including conjugation profile, payload distribution, linker stability, and free-payload levels.

Does BLENREP use a preservative?

The marketed vial is described as preservative-free. It is a single-dose lyophilized product that is reconstituted and diluted for intravenous infusion.[1]

Could a new excipient create a new BLENREP patent?

Potentially. A patent would require a novel and non-obvious formulation, process, presentation, or use supported by adequate technical data. The mere use of a known excipient in an ADC would generally provide a weaker basis than an unexpected stability or manufacturing result.

What is the most valuable BLENREP excipient opportunity?

The strongest opportunity is a qualified polysorbate 80 or alternative surfactant system supported by ADC-specific stability and particle data. The next strongest opportunities are trehalose supply, lyophilization optimization, and reduced-handling presentations.

References

1. U.S. Food and Drug Administration. (2023). BLENREP (belantamab mafodotin-blmf) prescribing information. GlaxoSmithKline.

2. U.S. Food and Drug Administration. (2020). FDA grants accelerated approval to belantamab mafodotin-blmf for relapsed or refractory multiple myeloma. https://www.fda.gov

3. U.S. Food and Drug Administration. (2025). Withdrawal of approval of BLENREP under the accelerated approval pathway. Federal Register and FDA drug database materials. https://www.fda.gov

4. GlaxoSmithKline plc. (2024). GSK announces positive headline results from the DREAMM-7 phase III trial of belantamab mafodotin in multiple myeloma. https://www.gsk.com

5. International Pharmaceutical Excipients Council Federation. (2020). Good manufacturing practices guide for pharmaceutical excipients. IPEC Federation.